EP4181938A1 - Combinaison de souches de lactobacilles et son utilisation en sante animale - Google Patents

Combinaison de souches de lactobacilles et son utilisation en sante animale

Info

Publication number
EP4181938A1
EP4181938A1 EP21755531.7A EP21755531A EP4181938A1 EP 4181938 A1 EP4181938 A1 EP 4181938A1 EP 21755531 A EP21755531 A EP 21755531A EP 4181938 A1 EP4181938 A1 EP 4181938A1
Authority
EP
European Patent Office
Prior art keywords
strain
mixture
microorganisms
salivarius
reuteri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21755531.7A
Other languages
German (de)
English (en)
French (fr)
Inventor
Nuria VIECO SAIZ
Ruth RASPOET
Eric Auclair
Djamel Drider
Frédérique GANCEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lesaffre et Cie SA
Universite Lille 2 Droit et Sante
Original Assignee
Lesaffre et Cie SA
Universite Lille 2 Droit et Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lesaffre et Cie SA, Universite Lille 2 Droit et Sante filed Critical Lesaffre et Cie SA
Publication of EP4181938A1 publication Critical patent/EP4181938A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Definitions

  • poultry we mean domestic birds belonging to the gallinaceans or even to the palmipeds which are bred for their meat, their eggs and their feathers.
  • the term “poultry” covers a wide range of birds, ranging from native and commercial chicken breeds to Muscovy ducks, mallards, turkeys, guinea fowl, geese, quails, pigeons, ostriches or pheasants. The most consumed poultry meat is chicken meat.
  • C. perfringens produces and secretes alpha-toxin (a-toxin), a lecithinase causing hemolysis and tissue necrosis, or even b-toxin (or Necrotic enteritis toxin B-like or NetB) causing the formation of endospores in the membrane of intestinal cells.
  • a-toxin alpha-toxin
  • b-toxin or Necrotic enteritis toxin B-like or NetB
  • lactic acid bacteria are widely used in the food industry as a biological food preservative or in factory farming for the prevention of infectious and zoonotic diseases. These bacteria are also used to improve the performance of animal husbandry through the production of digestive enzymes, volatile fatty acids and/or vitamins, which contribute to increasing the digestibility of nutrients and improving feed conversion rate. These lactic acid bacteria are notably found under the name of probiotics.
  • Lactic acid bacteria belong to the phylum Firmicutes, class Bacilli and order Lactobacillales.
  • the taxon called lactic acid bacteria includes cocci, Gram-positive bacilli or coccobacilli, non spondees, anaerobes or facultative aerobes with a G+C percentage of less than 50%. These bacteria are acidophilic with an optimum growth pH between 3.5 and 6.5. Most strains have nutritional requirements and require rich media to grow. This group includes 10 genera, the best known of which are Lactobacillus, Pediococcus, Lactococcus, Enterococcus, Streptococcus, Leuconostoc and Carnobacterium.
  • CN 105861399 also describes the use of a specific strain of Lb. plantarum to prevent necrotic enteritis in broiler chickens by inhibiting the growth of C. perfringens.
  • Document WO2006/133472 describes a complex mixture of 5 microorganisms inhibiting C. perfringens, consisting of E. faecium DSM 16211, L. reuteri DSM 16350, L. salivarius DSM 16351, P. acidilactici DSM 16210 and B. animalis DSM 16284. This document specifies that these specific strains of L. reuteri and L. salivarius are more effective in inhibiting E. coli than C. perfringens.
  • Document WO2016/170280 recommends the use of Bacteroides thetaiotaomicron, optionally combined with L. reuteri and/or L. salivarius, in particular to treat enteritis.
  • KLOSE et al. (Veterinary Microbiology, 2010, 144 (3-4): 515-21) have evaluated the antagonistic activity of various intestinal bacteria, including L. reuteri and L. salivarius, against C. perfringens and report a large heterogeneity between species.
  • the present invention relates to a mixture of microorganisms comprising a strain of Lactobacillus reuteri and a strain of Lactobacillus salivarius.
  • mixture is meant the association of at least 2 different species of microorganisms, advantageously of at least 2 distinct strains of bacteria, even more advantageously of at least 2 strains of lactic acid bacteria (lactobacilli or Lactobacillus ) distinct.
  • a mixture of microorganisms according to the invention may comprise one or more strains of Lb. reuteri and one or more strains of Lb. salivarius, and possibly other microorganisms, including other bacteria.
  • the specific mixture according to the invention is capable of reducing or inhibiting the growth and/or the activity of the bacterium C. perfringens.
  • growth of the bacterium C. perfringens is meant a set of mechanisms leading to an increase in the dry biomass of bacteria. It is the growth of the bacterial cell in size, mass and/or volume but also the growth of a population by cell division.
  • C. perfringens the pathogenic or even toxigenic activity of this bacterium. These include the production or secretion of toxins, such as NetB and a-toxin, or enzymes. It may also be the ability of C. perfringens to adhere to the gastrointestinal tract or even colonize it.
  • the mixture according to the invention allows a reduction or even an inhibition of the production and/or of the secretion of the toxins NetB and ⁇ -toxin.
  • the mixture according to the invention comprises or consists of:
  • the Bifidobacterium bacterium is chosen from the group consisting of: B. bifidum, B. longum, B. infantis, B.breve, B. adolescentis, B. animalis, B. lactis, and combinations thereof.
  • the Enterococcus bacterium is chosen from the group consisting of: E.faecium, E.faecalis, and their combinations
  • the Pediococcus bacterium is P. acidilactici.
  • the yeast is chosen from the group consisting of: Candida Kefyr, Saccharomyces florentinus, Saccharomyces cerevisiae, Saccharomyces cerevisiae var. boulardii, and combinations thereof.
  • the present invention relates to a composition
  • a composition comprising a mixture of microorganisms as defined above.
  • composition according to the invention may comprise the usual adjuvants or excipients used in the field considered, such as hydrophilic or lipophilic thickeners or gelling agents, palatables, hydrophilic or lipophilic additives, preservatives, antioxidants, diluents, vitamins, minerals, suspending agents, cellulosic derivatives, absorbents, cryoprotective agents or dyes.
  • adjuvants or excipients used in the field considered, such as hydrophilic or lipophilic thickeners or gelling agents, palatables, hydrophilic or lipophilic additives, preservatives, antioxidants, diluents, vitamins, minerals, suspending agents, cellulosic derivatives, absorbents, cryoprotective agents or dyes.
  • the composition according to the invention comprises at least one compound chosen from the following group: zeolites, calcium carbonate, calcium sulphate, magnesium carbonate, talc, trehalose, chitosan , shellac, albumin, starch, skimmed milk powder, whey, whey powder, maltodextrins, lactose, inulin, dextroses, celluloses, clays including sepiolite, derivatives of yeasts and cereals, vegetable oils or a solvent chosen from water or a physiological solution.
  • zeolites calcium carbonate, calcium sulphate, magnesium carbonate, talc, trehalose, chitosan , shellac, albumin, starch, skimmed milk powder, whey, whey powder, maltodextrins, lactose, inulin, dextroses, celluloses, clays including sepiolite, derivatives of yeasts and cereals, vegetable oils or a solvent chosen from water or
  • the mixture or the composition according to the invention is in dry or liquid form, in particular in freeze-dried, dried, pressed, liquid or frozen form, advantageously in freeze-dried form.
  • the mixture or composition according to the invention is intended to be administered orally.
  • the mixture or the composition may be in various suitable galenic forms, for example in the form of a lyophilisate to be poured and dissolved in drinking water, of a liquid to be poured over food or in water. drink, tablets, powder packaged in capsules or any other suitable form.
  • it is a powder or lyophilisate to be poured and dissolved in the drinking water of the animals.
  • the mixture or the composition according to the invention is added to the beverage or to the food so that the lactobacilli represent from 10 8 to 10 14 CFU/kg of the beverage or of the food, advantageously 10 10 to 10 12 CFU/kg.
  • - score 3 corresponds to an intestine showing large lesions visible through the outer wall of the intestinal tract.
  • the intake can be systematic for all animals from birth or can be decided upon the appearance of symptoms or even death in the farm.
  • the treatment is carried out as a preventive measure, that is to say before the appearance of any symptoms, as soon as the animals are born or after a few days. Even more advantageously, the treatment continues until the death of the animals, which generally occurs at 40 days for poultry.
  • the intake can take place once a day, or even at every drink intake or of food, or perhaps separated by several days.
  • it is taken daily.
  • a preferred dosage corresponds to daily administration, in the form of a food supplement at a concentration of 10 7 CFU/mL (equivalent to 10 7 CFU/g), throughout the life of the animal.
  • the strain of C. perfringens used in the example is a strain of C. perfringens isolated from a chicken suffering from necrotic enteritis.
  • the in vivo experiments took place for 17 days on 150 chickens (30 per experimental condition). The trial started on hatch day. During the tests, the lactobacilli were administered alone ⁇ Lb. reuteri, Lb. salivarius) or in combination ⁇ Lb. reuteri + Lb. salivarius), by gavage once a day, on days 1 and 2, then on day 10 to day 13.
  • Table 2 represents the approximate composition of diets (g/100g) 1-2/ Vaccination
  • the chickens of the group treated with the mixture of Lb. reuteri and Lb. salivarius have similar weights (753.13g) to those of the group of non-challenged chickens (765g), which are significantly different from the infected group (699.58g).
  • a significant decrease in intestinal lesions is obtained on the chickens of the group treated with the Lb mixture. reuteri and Lb. salivarius which present a score of lesions (1.00) similar to that of the group of non-challenged T- chickens (0.88) and significantly different from that of the infected T+ group (1.67).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP21755531.7A 2020-07-20 2021-07-19 Combinaison de souches de lactobacilles et son utilisation en sante animale Pending EP4181938A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2007632A FR3112557A1 (fr) 2020-07-20 2020-07-20 Combinaison de souches de lactobacilles et son utilisation en sante animale
PCT/FR2021/051348 WO2022018373A1 (fr) 2020-07-20 2021-07-19 Combinaison de souches de lactobacilles et son utilisation en sante animale

Publications (1)

Publication Number Publication Date
EP4181938A1 true EP4181938A1 (fr) 2023-05-24

Family

ID=73698948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21755531.7A Pending EP4181938A1 (fr) 2020-07-20 2021-07-19 Combinaison de souches de lactobacilles et son utilisation en sante animale

Country Status (7)

Country Link
US (1) US20230285476A1 (es)
EP (1) EP4181938A1 (es)
CN (1) CN116075237A (es)
BR (1) BR112023000712A2 (es)
FR (1) FR3112557A1 (es)
MX (1) MX2023000840A (es)
WO (1) WO2022018373A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115466699B (zh) * 2022-09-28 2023-03-31 成都大熊猫繁育研究基地 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用
CN117143783B (zh) * 2023-10-30 2024-03-22 杭州微致生物科技有限公司 一种唾液联合乳杆菌vb330及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT501919B1 (de) * 2005-06-14 2008-09-15 Erber Ag Probiotischer, gesundheits- bzw. leistungsfördernder futtermittel- und/oder trinkwasserzusatz für tiere sowie seine verwendung
TWI346554B (en) 2008-04-30 2011-08-11 Genmont Biotech Inc Lactobacillus isolates having anti-inflammatory activities and uses of the same
AT506877B1 (de) * 2008-05-23 2011-05-15 Erber Ag Probiotischer futtermittel- und/oder trinkwasserzusatz und verwendung
MX2010012786A (es) * 2008-05-23 2011-02-24 Erber Ag Alimento probiotico y/o aditivo de agua potable y uso del mismo.
CN103114051A (zh) * 2012-11-15 2013-05-22 上海交大昂立股份有限公司 一种罗伊氏乳杆菌及其应用
FR3035329A1 (fr) * 2015-04-23 2016-10-28 Agronomique Inst Nat Rech La prevention ou le traitement d'une infection par bacteroides thetaiotaomicron
CN105770355A (zh) * 2016-03-17 2016-07-20 青岛根源生物技术集团有限公司 一种预防肉鸡坏死性肠炎的复合制剂及其应用
CN105861399B (zh) 2016-06-17 2019-11-05 浙江大学 预防鸡坏死性肠炎的植物乳杆菌及其应用

Also Published As

Publication number Publication date
US20230285476A1 (en) 2023-09-14
WO2022018373A1 (fr) 2022-01-27
FR3112557A1 (fr) 2022-01-21
MX2023000840A (es) 2023-04-18
BR112023000712A2 (pt) 2023-01-31
CN116075237A (zh) 2023-05-05

Similar Documents

Publication Publication Date Title
US20180207165A1 (en) Methods and compositions for stimulating beneficial bacteria in the gastrointestinal tract
US9404162B2 (en) Feline probiotic bifidobacteria and methods
EP2754354B1 (en) Method for using a bacillus subtilis strain to enhance animal health
US9192177B2 (en) Feline probiotic Lactobacilli
KR101636096B1 (ko) 배변 회수·배변량 개선제
Shini et al. Probiotic Bacillus amyloliquefaciens H57 ameliorates subclinical necrotic enteritis in broiler chicks by maintaining intestinal mucosal integrity and improving feed efficiency
CN101171019A (zh) 免疫功能调节剂
EP2931289B1 (fr) Chitine ou ses derives pour la prevention et/ou le traitement de parasitoses
US11045509B2 (en) Tributyrin compositions and methods therefor
EP4181938A1 (fr) Combinaison de souches de lactobacilles et son utilisation en sante animale
JP2013538827A (ja) 腎機能を増強させるための組成物および方法
JP2022521576A (ja) バシラエン産生細菌またはその調製物を含有する組成物
Lorenzoni Poultry diseases influenced by gastrointestinal health: traditional treatments and innovative solutions
CA3198168A1 (fr) Composition symbiotique comme additif d'alimentation pour les porcelets ou les truies et son utilisation
AU2011202947B2 (en) Feline probiotic lactobacilli
JP6487106B1 (ja) 免疫機能向上用食品組成物
WO2023036957A1 (fr) Utilisation de faecalibacterium pour traiter une infection par un virus respiratoire
EP3669007A1 (fr) Souches de lactobacillus stimulant la croissance
FR3138770A1 (fr) Ensemble de parties destine a moduler le microbiote intestinale, reduire la prise de poids et le stockage des graisses dans le foie
FR3078609A1 (fr) Composition pour diminuer la sensibilite au gluten
JP2019094313A (ja) 腹部膨満感改善用組成物及び腹部膨満感改善作用を有する物質又は組成物をスクリーニングする方法
FR3068711A1 (fr) Extrait de fenugrec pour la stimulation quantitative et dans le temps de la croissance de bacteries benefiques pour l’homme et pour l’animal
WO2017137547A1 (fr) Composition probiotique permettant de favoriser la croissance juvénile de l'animal d'élevage

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)